

The effect of "UCB1577571 and CA050_01953" in the transplant model of psoriasis.

Published: 03-05-2016

Last updated: 16-04-2024

The aim of the project is to study the effect of "UCB1577571 en CA050_01953" on typical skin features of psoriasis. This information can establish the most effective compound, right formulation and dose for further clinical research.

Ethical review	Approved WMO
Status	Will not start
Health condition type	Epidermal and dermal conditions
Study type	Observational invasive

Summary

ID

NL-OMON43021

Source

ToetsingOnline

Brief title

Transplant model of psoriasis

Condition

- Epidermal and dermal conditions

Synonym

psoriasis

Research involving

Human

Sponsors and support

Primary sponsor: Derphartox

Source(s) of monetary or material Support: Farmaceutische industrie

Intervention

Keyword: model, psoriasis, transplant

Outcome measures

Primary outcome

Effect on typical psoriasis skin features after treatment with "UCB1577571 en CA050_01953".

Secondary outcome

-

Study description

Background summary

Psoriasis is an autoimmune disease in which proinflammatory protein mediators, released by skin cells and infiltrating cells, cause an abnormal cell division and differentiation. It may be possible to treat psoriasis using drugs aimed at preventing the synthesis of such mediators.

Study objective

The aim of the project is to study the effect of "UCB1577571 en CA050_01953" on typical skin features of psoriasis. This information can establish the most effective compound, right formulation and dose for further clinical research.

Study design

Lesional skin biopsies of 5 mm in diameter will be treated with "UCB1577571 en CA050_01953" using the transplant model of psoriasis. By measuring the effect on typical psoriasis skin features, it is possible to establish the most effective compound, the right formulation and dose for further clinical research.

Study burden and risks

The health risks associated with taking blood & skin biopsies are small. It is possible to obtain a slight scar formation and/or discolouration at the site of

the biopsy punch.

Contacts

Public

Derphartox

Wytemaweg 80
Rotterdam 3015 CN
NL

Scientific

Derphartox

Wytemaweg 80
Rotterdam 3015 CN
NL

Trial sites

Listed location countries

Netherlands

Eligibility criteria

Age

Adults (18-64 years)

Elderly (65 years and older)

Inclusion criteria

Patients with moderate to severe psoriasis

Exclusion criteria

Volunteers undergoing UV/light therapy or taking systemic drugs such as cyclosporin A or methotrexate

Volunteers using local topical corticosteroids

Volunteers developing psoriasis at wound sites (Köbner phenomenon)

Study design

Design

Study type: Observational invasive

Masking: Open (masking not used)

Control: Uncontrolled

Primary purpose: Other

Recruitment

NL

Recruitment status: Will not start

Enrollment: 18

Type: Anticipated

Ethics review

Approved WMO

Date: 03-05-2016

Application type: First submission

Review commission: METC Leiden-Den Haag-Delft (Leiden)

metc-ldd@lumc.nl

Study registrations

Followed up by the following (possibly more current) registration

No registrations found.

Other (possibly less up-to-date) registrations in this register

No registrations found.

In other registers

Register

CCMO

ID

NL57476.098.16